Study met the primary endpoint and all secondary endpoints, highly consistent with rapid response from the INTEGUMENT-1 and INTEGUMENT-2 pivotal trials For the primary endpoint, 25.4% of children ...
New INTEGUMENT-1 and INTEGUMENT-2 data show a rapid and significant reduction in itch as early as 24 hours after the first application of roflumilast cream 0.15% Rapid and significant improvements ...
A total of 654 adults and children, age six and older, have been enrolled in the INTEGUMENT-1 trial Enrollment continues in INTEGUMENT-2 with topline data from both trials expected by end of 2022 ...
Daily application of roflumilast cream for 52 weeks improves the signs and symptoms of AD in patients with various comorbid atopic conditions.
Full data results will be presented at future medical conferences and in peer-reviewed journals. The INTEGUMENT-1 study met the primary endpoint and all secondary endpoints. Topline results were ...
Roflumilast cream 0.05% showed durable efficacy and long-term tolerability in children aged 2 to 5 years with atopic dermatitis over 56 weeks. The cream demonstrated high application-site tolerability ...
A total of 652 children, ages 2 to 5, were enrolled in the study Topline data expected in the third quarter Atopic dermatitis (AD) affects approximately 26 million adults and children in the United ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results